jiayi-li23/proxann_data huggingface dataset:
Bill 110-S-1359 — Health / R&D
Subject: Health

Lupus Research, Education, Awareness, Communication, and Healthcare Amendments of 2007 - Amends the Public Health Service Act to require the Director of the National Institute of Arthritis and Musculoskeletal and Skin Diseases to expand research on lupus to include: (1) basic research to discover the pathogenesis and pathophysiology of the disease; and (2) research to validate lupus biomarkers. Requires the Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention (CDC), to work with a consortium of academic health institutions to undertake an epidemiological study to determine the prevalence and incidence of lupus in the United States. Requires the Director of CDC to: (1) enter into a cooperative agreement with such consortium to develop, implement, and manage a system for lupus data collection and analysis; and (2) ensure that such consortium represents different geographic areas and includes individuals of racial and ethnic backgrounds disproportionately affected by lupus. Requires the Secretary to enter into a contract with the Institute of Medicine to study and make recommendations related to lupus, to include: (1) evaluating federal and state activities related to lupus and recommending ways to expand such activities; (2) identifying gaps in federal research; and (3) recommending ways to improve the quality of life for people with lupus. Requires the Secretary, acting through the Director of the Office on Women's Health, to conduct and support a national lupus public awareness and health professional education campaign, with an emphasis on reaching populations at highest risk for the disease.
Bill 110-S-1382 — Health / R&D
Subject: Health

ALS Registry Act - (Sec. 2) Amends the Public Health Service Act to authorize the Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention (CDC), if scientifically advisable, to: (1) develop a system to collect data on amyotrophic lateral sclerosis (ALS) and other motor neuron disorders that can be confused with ALS, misdiagnosed as ALS, or progress to ALS; and (2) establish a national registry for the collection and storage of such data to develop a population-based registry of cases. Authorizes the Secretary, acting through the Director, to establish the Advisory Committee on the National ALS Registry, which may review information and make recommendations to the Secretary concerning: (1) the development and maintenance of the registry; (2) the type of information to be included; (3) the manner in which data is to be collected; (4) the use and availability of such data; and (5) the collection of information about diseases and disorders that primarily affect motor neurons that are considered essential to furthering the study and cure of ALS. Allows the Secretary, acting through the Director, to award grants to, and enter into contracts and cooperative agreements with, public or private nonprofit entities for the collection, analysis, and reporting of data on ALS and other motor neuron disorders. Authorizes the Secretary, acting through the Director, to: (1) identify, build upon, expand, and coordinate among existing data and surveillance systems, surveys, registries, and other federal public health and environmental infrastructure wherever possible; and (2) provide for research access to ALS data as recommended by the Advisory Committee in a manner that protects personal privacy. Allows the Secretary to ensure that epidemiological and other types of information is made available to the National Institutes of Health (NIH) and the Department of Veterans Affairs (VA). (Sec. 3) Authorizes the Secretary to report to the appropriate congressional committees on ALS registries, including: (1) the registries currently under way and future planned registries; (2) the criteria involved in determining what registries to conduct, defer, or suspend; (3) the scope of those registries; and (4) the activities the Secretary undertakes to establish partnerships with research and patient advocacy communities to expand registries.
Bill 110-S-1398 — Health / R&D
Subject: Health

Inflammatory Bowel Disease Research Enhancement Act - Requires the Director of the National Institute of Diabetes and Digestive and Kidney Diseases to expand, intensify, and coordinate the Institute's research activities on inflammatory bowel disease, with a focus on: (1) genetic research on susceptibility for inflammatory bowel disease; (2) research targeted to increase knowledge about the causes and complications of inflammatory bowel disease in children; (3) animal model research; (4) clinical research; (5) expansion of the Institute's Inflammatory Bowel Disease Centers program with a focus on pediatric research; (6) training of qualified health professionals in biomedical research focused on inflammatory bowel disease; and (7) other research priorities identified in specified scientific agendas.Requires the Director of the Centers for Disease Control and Prevention (CDC) to expand the Inflammatory Bowel Disease Epidemiology Program to include additional studies focused on: (1) the incidence and prevalence of pediatric inflammatory bowel disease in the United States; (2) genetic and environmental factors associated with the disease; (3) age, race or ethnicity, gender, and family history of individuals diagnosed with the disease; and (4) treatment approaches and outcomes.
Bill 110-S-1413 — Health / R&D
Subject: Health

Uterine Fibroid Research and Education Act of 2007 - Requires the Director of the National Institutes of Health (NIH) to expand, intensify, and coordinate programs for the conduct and support of uterine fibroids research. Directs the Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention (CDC), to develop and disseminate to the public information regarding uterine fibroids, including information on: (1) the incidence and prevalence of uterine fibroids among women; (2) the elevated risk for minority women; and (3) the availability of a range of treatment options. Requires the Secretary, acting through the Administrator of the Health Resources and Services Administration (HRSA), to develop and disseminate uterine fibroids information to health care providers.
Bill 110-S-1421 — Health / R&D
Subject: Armed forces and national security

Directs the Medical Follow-Up Agency of the Institute of Medicine of the National Academy of Sciences (Agency) to maintain and manage the assets (including electronic data files and biological specimens of study participants) transferred to the Agency from the Air Force Health Study. Authorizes the Agency, during FY2007-FY2011, to conduct additional research on such assets toward the goal of understanding the determinants of health, and promoting wellness, in veterans. Requires an Agency report to Congress assessing the feasibility and advisability of conducting additional research on such assets after the end of FY2011.
Bill 110-S-1459 — Health / R&D
Subject: Health

Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2007 - Requires the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health (NIH), to expand and intensify research and related NIH activities with respect to psoriasis and psoriatic arthritis. Requires the Director of the National Institute of Arthritis and Musculoskeletal and Skin Diseases to conduct or support research to expand understanding of the causes of, and to find a cure for, psoriasis and psoriatic arthritis. Requires the Secretary, acting through the Director of the Centers for Disease Control and Prevention (CDC), to establish a national psoriasis and psoriatic arthritis patient registry. Directs the Secretary to: (1) enter into cooperative agreements to develop, implement, and manage a system for psoriasis and psoriatic arthritis patient data collection and analysis; (2) ensure the collection and analysis of longitudinal data related to individuals of all ages; (3) convene a summit on current federal activities to conduct or support research, treatment, education, and quality-of-life activities with respect to psoriasis and psoriatic arthritis; and (4) enter into an agreement with the Institute of Medicine to study insurance coverage of psoriasis and psoriatic arthritis.
Bill 110-S-1734 — Health / R&D
Subject: Health

Prostate Research, Imaging, and Men's Education Act or the PRIME Act - Requires the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health (NIH), to expand and intensify research to develop advanced imaging technologies for prostate cancer detection, diagnosis, and treatment comparable to mammogram technology.Directs the Secretary: (1) to carry out a national campaign to increase awareness and knowledge with respect to the need for prostate cancer screening and for improved detection technologies; (2) in developing such campaign, to recognize and address the racial disparities in the incidences of prostate cancer and mortality rates; (3) to establish a program to award grants to nonprofit private entities to test alternative outreach and education strategies; (4) to carry out research to develop an improved prostate cancer screening blood test using in-vitro detection; and (5) to certify compliance with this Act within one year.
Bill 110-S-2042 — Health / R&D
Subject: Health

SMA Treatment Acceleration Act - Requires the Director of the National Institutes of Health (NIH) to upgrade and unify existing spinal muscular atrophy (SMA) clinical trial sites to establish a national clinical trials network for SMA. Requires the Director of NIH to ensure that such network: (1) conducts coordinated, multisite, clinical trials of pharmacological approaches to the treatment of SMA; and (2) rapidly and effectively disseminates scientific findings to the field.Requires the Director of NIH to: (1) establish an SMA data coordinating center; and (2) expand and intensify NIH programs with respect to preclinical translation research and medicinal chemistry related to SMA.Requires the Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention (CDC), to enhance and provide ongoing support to the existing SMA patient registry to provide for expanded research on the epidemiology of SMA. Directs the Secretary to ensure the collection and analysis of longitudinal data related to individuals of all ages with SMA.Requires the Secretary to establish the Spinal Muscular Atrophy Coordinating Committee to: (1) coordinate activities across NIH and with other federal health programs and activities relating to SMA; and (2) conduct a study to identify barriers to the development of drugs for treating SMA and similar genetic disorders.Requires the Director of NIH to establish a trans-National Institutes of Health cooperative research initiative on SMA to ensure the success of the SMA projects led by the National Institute of Neurological Disorders and Stroke. Requires the Secretary to submit recommendations to Congress to improve and expand on incentives provided under the Orphan Drug Act and related statutes to promote SMA drug development.
Bill 110-S-2175 — Health / R&D
Subject: Health

Family Asthma Act - Amends the Public Health Service Act to authorize the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health (NIH), to award grants to eligible entities to conduct pilot projects to prevent and control asthma symptoms and to reduce asthma attacks and improve self-management for individuals and families. Requires the Secretary to give: (1) priority to entities that serve a medically underserved population; and (2) consideration to an adequate rural-urban distribution, so as to gain better information about asthma at the national level. Authorizes additional appropriations to the National Heart, Lung, and Blood Institute to develop a National Asthma Action Plan and to fund a report to Congress by the National Asthma Education and Prevention Program. Requires the Secretary, acting through the Director of the Centers for Disease Control and Prevention (CDC), to: (1) collaborate with state and local health departments to conduct activities to inform and educate the public regarding asthma; (2) conduct asthma surveillance activities to collect data on the prevalence and severity of asthma, the effectiveness of public heath asthma intervention, and the quality of asthma management; and (3) compile and annually publish asthma data. Requires the Director of the National Institute of Environmental Health Sciences to establish Dr. Irving J. Selikoff individual and institutional training grants for education and training of health care providers on the role of environmental factors in the development and prevention of asthma and recurrent asthma attacks.
Bill 110-S-2210 — Health / R&D
Subject: Health

Medical Innovation Prize Act of 2007 - Prohibits any person from having the right to exclusively manufacture, distribute, sell, or use in interstate commerce a drug, a biological product, or a drug or biological product manufacturing process, including the exclusive right to rely on health registration data or the 30-month stay-of-effectiveness period for Orange Book patents under the Federal Food, Drug, and Cosmetic Act, notwithstanding provisions of that Act and other specified laws. Establishes the Fund for Medical Innovation Prizes. Requires the Board of Trustees for the Fund to award prize payments for medical innovations relating to a drug, biological product, or manufacturing process. Requires an eligible award recipient to be either the first person to receive market clearance or the holder of the patent. Directs the Board to consider: (1) the number of patients who benefited from the drug, including non-U.S. patients; (2) the incremental therapeutic benefit of the drug to treat the same disease or condition, except that the Board shall provide for cases where drugs, biological products, or manufacturing processes are developed at roughly the same time so that the comparison is to products that were not recently developed; (3) the degree to which the drug addresses priority health care needs, such as global infectious diseases and neglected diseases that primarily afflict the poor in developing countries; and (4) the improved efficiency of manufacturing processes for drugs or biological processes. Allows the Board to award prize payments for no more than ten years. Allocates certain minimum payments from the Fund for priority research and development.Requires the Comptroller General to conduct an audit to determine the Board's effectiveness in bringing to market new drugs, vaccines, biological products, and manufacturing processes in a cost-effective manner and in addressing society's global medical needs.
Bill 110-S-2351 — Health / R&D
Subject: Taxation

Amends the Internal Revenue Code to allow a general business tax credit for 50% of expenses paid for research and development of any qualified infectious disease product. Defines "qualified infectious disease product" as any antibiotic drug, antiviral, diagnostic test, biological product, or vaccine developed to treat, detect, prevent, or identify certain pathogens. Terminates such credit after 2012.
Bill 110-S-2479 — Health / R&D
Subject: Health

Catalyst to Better Diabetes Care Act of 2007 - Requires the Secretary of Health and Human Services (the Secretary) to: (1) review uptake and utilization of diabetes screening benefits to identify and address problems with utilization and data collection mechanisms; (2) establish an outreach program to identify existing efforts to increase awareness among seniors and providers of such benefits; and (3) maximize cost-effectiveness in increasing utilization of such benefits.Requires the Secretary of Health and Human Services to establish an advisory group to examine and recommend best practices of employee wellness and disease management programs.Directs the Secretary to prepare, biennially, a diabetes report card for the nation and for each state.Requires the Secretary, acting through the Director of the Centers for Disease Control and Prevention (CDC), to: (1) promote the education and training of physicians on how to properly complete birth and death certificates and the importance of such data; (2) encourage state adoption of the latest standard revisions of birth and death certificates; and (3) work with states to reengineer their vital statistics systems to provide cost-effective, timely, and vital systems data. Allows the Secretary to promote improvements to the collection of diabetes mortality data.Requires the Secretary to conduct a study of the impact of diabetes on the practice of medicine in the United Sates and the level of diabetes medical education that should be required prior to licensure, board certification, and board recertification.
Bill 110-S-2569 — Health / R&D
Subject: Health

Ovarian Cancer Biomarker Research Act of 2008 - Amends the Public Health Service Act to require the Director of the National Cancer Institute to enter into cooperative agreements with, or make grants to, public or nonprofit entities to establish and operate centers to conduct research on biomarkers for use in risk stratification for, and the early detection and screening of, ovarian cancer. Designates each center as an Ovarian Cancer Biomarker Center of Excellence.Allows federal payments under such an agreement or grant to be used for research on: (1) the development and characterization of new biomarkers and the refinement of existing biomarkers; (2) the clinical and laboratory validation of such biomarkers; (3) the development and implementation of clinical and epidemiological research on the utilization of such biomarkers; and (4) the development and implementation of repositories for new tissue, urine, serum, and other biological specimens.Requires the Director to: (1) make available for research banked serum and tissue specimens from clinical research regarding ovarian cancer that was funded by the Department of Health and Human Services (HHS); (2) establish an Ovarian Cancer Biomarker Clinical Trial Committee, which shall be established and operated in consultation with the Gynecologic Oncology Group, to assist the Director to design and implement national clinical trials to determine the utility of such biomarkers; and (3) establish a national data center to conduct statistical analyses of trial data.
Bill 110-S-2584 — Health / R&D
Subject: International affairs

PEPFAR Accountability and Transparency Act - Amends the United States Leadership Against HIV/AIDS, Tuberculosis, and Malaria Act of 2003 to direct the Coordinator of United States Government Activities to Combat HIV/AIDS Globally to: (1) establish a mechanism to evaluate global HIV/AIDS programs financed by the U.S. government in order to improve accountability, increase transparency, and ensure the delivery of evidence-based services; and (2) develop a five-year strategic plan for program monitoring, operations research, and impact evaluation research.
Bill 110-S-2618 — Health / R&D
Subject: Health

Paul D. Wellstone Muscular Dystrophy Community Assistance, Research, and Education Amendments of 2008 - Amends the Public Health Service Act to designate centers of excellence for research on various forms of muscular dystrophy as Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers. Requires the Muscular Dystrophy Interagency Coordinating Committee to give special consideration to enhancing the clinical research infrastructure required to test emerging therapies for the various forms of muscular dystrophy. Requires the Secretary of Health and Human Services to ensure that any data on patients that is collected as part of the Muscular Dystrophy Surveillance, Tracking and Research Network (MD STARnet) is regularly updated to reflect changes in patient condition over time. Requires the Director of the Centers for Disease Control and Prevention (CDC) to: (1) report to the appropriate congressional committees on MD STARnet and data collection; and (2) make publicly available prospective health outcome data on the health and survival of people with muscular dystrophy. Requires the Director of CDC, in carrying out a program to provide information and education on muscular dystrophy to health professionals and the general public, to: (1) partner with leaders in the muscular dystrophy patient community; and (2) widely disseminate the Duchenne-Becker muscular dystrophy care considerations. Requires the Director of the Agency for Healthcare Research and Quality to: (1) evaluate the available scientific evidence to develop and issue an initial set of care considerations for Duchenne-Becker muscular dystrophy and provide ongoing review and updates where appropriate; and (2) replicate the same systematic review methodology used to develop such care considerations as a model for other muscular dystrophies.
Bill 110-S-2629 — Health / R&D
Subject: Health

Nino's Act - Amends title XIX (Medicaid) of the Social Security Act to provide for mandatory Medicaid coverage of drugs prescribed for certain research study child participants, regardless of Medicaid eligibility otherwise, if the state provides drug coverage.
Bill 110-S-2863 — Health / R&D
Subject: Taxation

Ethical Stem Cell Research Tax Credit Act of 2008 - Amends the Internal Revenue Code to allow a tax credit for 30% of qualified stem cell research expenses paid or incurred in a taxable year. Defines "qualified stem cell research expenses" as expenses for carrying out basic and applied research to develop techniques for the isolation, derivation, production, testing, and human clinical use of stem cells that may result in improved understanding of or treatments for diseases and other adverse health conditions. Prohibits a tax credit for any research expenses that may involve: (1) the creation of a human embryo for research purposes; (2) the destruction of or discarding of, or risk of injury to, a human embryo; or (3) the use of any stem cell for prohibited purposes.
Bill 110-S-2877 — Health / R&D
Subject: Health

Pediatric, Adolescent, and Young Adult Cancer Survivorship Research and Quality of Life Act of 2008 - Amends the Public Health Service Act to direct the Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention (CDC), to expand and intensify CDC's cancer control programs. Requires the Secretary to: (1) provide guidance to states, in collaboration with the Director of the National Cancer Institute (NCI), on interventions that may be incorporated into state cancer control programs to improve the long-term health status of childhood cancer survivors; (2) encourage states to incorporate strategies for improving their care into their comprehensive cancer plans; (3) collaborate with the NCI Director to improve or develop systems for tracking cancer survivors; and (4) enhance control programs to include a focus on childhood cancer survivorship. Directs the NCI Director to: (1) coordinate National Institutes of Health (NIH) activities regarding cancer survivorship; (2) make grants for research regarding pediatric cancer survivors and health disparities in cancer survivorship within minority populations; (3) conduct or support research to evaluate follow-up care for childhood cancer survivors; and (4) make grants to establish pilot programs to develop, study, or evaluate model systems for monitoring and caring for cancer survivors. Directs the Secretary to make grants to: (1) establish or improve training programs for health care professionals to improve follow-up care for young cancer survivors and to ensure that such care is linguistically and culturally competent; (2) pay costs incurred during the first four years of operating a clinic for comprehensive long-term followup services for childhood cancer survivors; and (3) improve physical and psychosocial care for such survivors.